OVERVIEW

Simply Speaking® Rhuematoid Arthritis is organized by Practice Point Communications (PPC).

Accreditation:
Physicians:
Rush University Medical Center designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

ANCC Credit Designation - Nurses:
The maximum number of hours awarded for this CE activity is 1 contact hours. Rush University designates this live activity for 1 Continuing Education credit(s). This activity is being presented without bias and with commercial support.

Pharmacists:
This activity is accredited for 1 hour of continuing pharmacy education (CPE) credit. Rush University Medical Center will report all credit to CPE Monitor within 60 working days after receiving evidence of successful completion of the course.

Overview:
What is Simply Speaking® Rhuematoid Arthritis?
• An educational series accredited by Rush University Medical Center (RUMC)
• Live, accredited CME and CE activities compliant with evolving ACCME guidelines
• Regional educational opportunities for MD, DO, PA, NP, RN and PharmD/RPh healthcare professionals
• Dedicated RUMC Course Director and Planning Committee that meets quarterly to discuss process, logistics, and content enhancements and ongoing ACCME compliance
• A proven process of identifying, certifying and evaluating national and regional healthcare experts

Why participate in Simply Speaking® Rhuematoid Arthritis?
• Content development and training provided by well-known and credible Educators participating within Simply Speaking®
• This series is available free of charge to a variety of institutions (clinics, hospitals, specialty organizations) wanting to improve health care provider education

Topics:
New and Emerging Treatments and Management Approaches in RA:
Prompt initiation of DMARD therapy results in higher rates of remission or low disease activity in patients with rheumatoid arthritis (RA). Despite significantly improved outcomes in RA, there is no cure--underscoring the need for individualized therapy, development of new agents, and approaches to prevent/cure RA. This activity will discuss new and emerging treatments for RA, data on when to initiate treatment as it relates to RA prevention, and clinical considerations impacting individualized therapy for patients with RA.

Optimizing Patient Management in RA: A Case-Based Approach:
An array of targeted biologic therapies and new targeted oral small molecule agents have been approved to treat rheumatoid arthritis (RA). Many clinical scenarios necessitate collaborative decision-making to understand the appropriate role of existing and new treatments in the care for patients with RA. This activity will use a case-based approach to discuss considerations that impact the selection of conventional synthetic, targeted biologic, and targeted synthetic DMARDs in patients with RA who have early-active disease, late-active disease, and resistant disease.

Post Conference Update from ACR Convergence 2020: American College of Rheumatology:
Effective strategies for rheumatoid arthritis (RA) continue to evolve, however there are no drugs that are universally effective for all patients. Management approaches for many clinical scenarios are not specifically/adequately addressed by current treatment guidelines, necessitating consideration of the most recent clinical trial data. Awareness of advances in RA knowledge base place healthcare professionals at the forefront of RA care. This activity will explain how recent study results in RA apply to clinical practice; discuss significant developments and strategies in RA pathogenesis, measurement, and therapy; and discuss results from key clinical studies on existing and investigational RA agents.

Rheumatoid Arthritis Post Conference Update from European League Against Rheumatism (EULAR) 2020:
Effective strategies for rheumatoid arthritis (RA) continue to evolve, however there are no drugs that are universally effective for all patients. Management approaches for many clinical scenarios are not specifically/adequately addressed by current treatment guidelines, necessitating consideration of the most recent clinical trial data. Awareness of advances in RA knowledge base place healthcare professionals at the forefront of RA care. This activity will explain how recent study results in RA apply to clinical practice; discuss significant developments and strategies in RA pathogenesis, measurement, and therapy; and discuss results from key clinical studies on existing and investigational RA agents.